Pharmacokinetics of -Inositol in a Wistar Rat Animal Model

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Oct 14

PMID 36232547

Authors

Tomasz Antonowski

Adam Osowski

Damian Szczesny

Joanna Szablinska-Piernik

Jerzy Juskiewicz

Leslaw Lahuta

Andrzej Rynkiewicz

Joanna Wojtkiewicz

Affiliations

Soon will be listed here.

Abstract

-inositol is the most popular inositol in living organisms, where it is present as a sugar alcohol, in a free form, and can also be described as a lipid. The aim of this study was to check the concentration change of a myo-inositol solution from the time of oral administration and over a 48 h period in Wistar-type rats. All rats received 2 g/kg of inositol as a solution in distilled water by oral gavage. Estimated parameters were based on the serum concentration of myo-inositol observed in nine individual rats with regard to time. Observations were described as a one-compartment pharmacokinetic model with first-order absorption and zero-order endogenous input of checked inositol. The highest myo-inositol concentration was observed in the first hour after oral administration in the serum of all tested rats. Then, the concentration began decreasing immediately after the maximal peak. The inositol concentration continued to decrease, but after 24 h its level was still higher than before the administration. The plasma profile of the myo-inositol concentration showed a rapid decline over time, possibly due to the metabolism of this compound.

Citing Articles

Cordycepin Ameliorates High Fat Diet-Induced Obesity by Modulating Endogenous Metabolism and Gut Microbiota Dysbiosis.

Fu Y, Wang Q, Tang Z, Liu G, Guan G, Lyu J Nutrients. 2024; 16(17).

PMID: 39275176 PMC: 11396883. DOI: 10.3390/nu16172859.

and assessment of an optimized QbD-guided myoinositol and metformin-loaded mucus-penetrating particle-based gel for the amelioration of PCOS.

Farooq U, Aamir Mirza M, Alshetaili A, Mohapatra S, Jain P, Hassan N Nanoscale Adv. 2024; 6(2):648-668.

PMID: 38235090 PMC: 10791119. DOI: 10.1039/d3na00943b.

References

Martin K, Mani M, Mani A . New targets to treat obesity and the metabolic syndrome. Eur J Pharmacol. 2015; 763(Pt A):64-74. PMC: 4573317. DOI: 10.1016/j.ejphar.2015.03.093. View

Navarro J, Decara J, Medina-Vera D, Tovar R, Suarez J, Pavon J . D-Pinitol from Is an Orally Active Natural Inositol That Reduces Pancreas Insulin Secretion and Increases Circulating Ghrelin Levels in Wistar Rats. Nutrients. 2020; 12(7). PMC: 7400942. DOI: 10.3390/nu12072030. View

Szkudelski T, Kandulska K . The effect of myo-inositol on ethanol-induced metabolic changes and insulin concentration in the rat. Arch Physiol Biochem. 2000; 107(4):334-7. DOI: 10.1076/13813455199908107041qft334. View

Phelps D, Ward R, Williams R, Watterberg K, Laptook A, Wrage L . Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. Pediatr Res. 2013; 74(6):721-9. PMC: 3962781. DOI: 10.1038/pr.2013.162. View

Moreira L, Feltrin C, Goncalves J, de Castro W, SimOes C, de Padua R . Determination of l-(+)-bornesitol, the hypotensive constituent of Hancornia speciosa, in rat plasma by LC-MS/MS and its application on a pharmacokinetic study. Biomed Pharmacother. 2020; 132:110900. DOI: 10.1016/j.biopha.2020.110900. View

Antonowski T, Osowski A, Lahuta L, Gorecki R, Rynkiewicz A, Wojtkiewicz J . Health-Promoting Properties of Selected Cyclitols for Metabolic Syndrome and Diabetes. Nutrients. 2019; 11(10). PMC: 6835238. DOI: 10.3390/nu11102314. View

Capasso I, Esposito E, Maurea N, Montella M, Crispo A, De Laurentiis M . Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trials. 2013; 14:273. PMC: 3765513. DOI: 10.1186/1745-6215-14-273. View

Croze M, Soulage C . Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013; 95(10):1811-27. DOI: 10.1016/j.biochi.2013.05.011. View

Facchinetti F, Bizzarri M, Benvenga S, DAnna R, Lanzone A, Soulage C . Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. Eur J Obstet Gynecol Reprod Biol. 2015; 195:72-76. DOI: 10.1016/j.ejogrb.2015.09.024. View

10.

Unfer V, Facchinetti F, Orru B, Giordani B, Nestler J . Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017; 6(8):647-658. PMC: 5655679. DOI: 10.1530/EC-17-0243. View

11.

Hung W, Chang W, Lu W, Wei G, Wang Y, Ho C . Pharmacokinetics, bioavailability, tissue distribution and excretion of tangeretin in rat. J Food Drug Anal. 2018; 26(2):849-857. PMC: 9322208. DOI: 10.1016/j.jfda.2017.08.003. View

12.

Song F, Su H, Yang N, Zhu L, Cheng J, Wang L . Myo-Inositol content determined by myo-inositol biosynthesis and oxidation in blueberry fruit. Food Chem. 2016; 210:381-7. DOI: 10.1016/j.foodchem.2016.04.099. View

13.

Fan J, de Lannoy I . Pharmacokinetics. Biochem Pharmacol. 2013; 87(1):93-120. DOI: 10.1016/j.bcp.2013.09.007. View

14.

Urso R, Blardi P, Giorgi G . A short introduction to pharmacokinetics. Eur Rev Med Pharmacol Sci. 2003; 6(2-3):33-44. View

15.

Bizzarri M, Fuso A, Dinicola S, Cucina A, Bevilacqua A . Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metab Toxicol. 2016; 12(10):1181-96. DOI: 10.1080/17425255.2016.1206887. View

16.

Lin X, Ma L, Gopalan C, Ostlund R . d- chiro-Inositol is absorbed but not synthesised in rodents. Br J Nutr. 2009; 102(10):1426-34. PMC: 3760478. DOI: 10.1017/S0007114509990456. View

17.

Chatree S, Thongmaen N, Tantivejkul K, Sitticharoon C, Vucenik I . Role of Inositols and Inositol Phosphates in Energy Metabolism. Molecules. 2020; 25(21). PMC: 7663797. DOI: 10.3390/molecules25215079. View